Funder: CurePSP
Due Dates: December 15, 2026, 5:00 PM US Eastern Time (Letter of Intent) | March 31, 2027, 5:00 PM US Eastern Time (Invited full proposal)
Funding Amounts: Up to $500,000 per project for up to three years; no indirect costs
Summary: Supports translation and validation of existing PSP biomarker discoveries for research and clinical use.
Key Information: Projects must focus exclusively on PSP and build on existing discoveries, rather than exploratory biomarker discovery.
Description
CurePSP’s Biomarker Accelerator Program funds the next steps needed to move existing progressive supranuclear palsy (PSP) biomarker discoveries into research or clinical settings. It addresses the lack of reliable biomarkers for diagnosis, disease monitoring and treatment-response assessment, which contributes to misdiagnosis, delays in care and difficulties measuring treatment effectiveness in clinical trials.
Projects may validate or replicate findings, develop standardized assays or tools, or integrate biomarkers across modalities. Existing discoveries may come from preclinical models, fluids, tissue, proteomics, imaging, genetic data or other approaches. Diagnostic biomarkers are a primary goal, but the program accepts other contexts of use that advance PSP research or clinical care, including monitoring and prognosis. Its emphasis is on translational, scalable work connecting laboratory discoveries with patient care.
